Literature DB >> 26140454

Under Pressure: Financial Effect of the Hospital-Acquired Conditions Initiative-A Statewide Analysis of Pressure Ulcer Development and Payment.

Jennifer Meddings1, Heidi Reichert1, Mary A M Rogers1, Timothy P Hofer1,2, Laurence F McMahon1,3, Kyle L Grazier3.   

Abstract

OBJECTIVES: To assess the financial effect of the 2008 Hospital-Acquired Conditions Initiative (HACI) pressure ulcer payment changes on Medicare, other payers, and hospitals.
DESIGN: Retrospective before-and-after study of all-payer statewide administrative data for more than 2.4 million annual adult discharges in 2007 and 2009 using the Healthcare Cost and Utilization Project State Inpatient Datasets for California. How often and by how much the 2008 payment changes for pressure ulcers affected hospital payment was assessed.
SETTING: Nonfederal acute care California hospitals (N = 311). PARTICIPANTS: Adults discharged from acute-care hospitals. MEASUREMENTS: Pressure ulcer rates and hospital payment changes.
RESULTS: Hospital-acquired pressure ulcer rates were low in 2007 (0.28%) and 2009 (0.27%); present-on-admission pressure ulcer rates increased from 2.3% in 2007 to 3.0% in 2009. According to clinical stage of pressure ulcer (available in 2009), hospital-acquired Stage III and IV ulcers occurred in 603 discharges (0.02%); 60,244 discharges (2.42%) contained other pressure ulcer diagnoses. Payment removal for Stage III and IV hospital-acquired ulcers reduced payment in 75 (0.003%) discharges, for a statewide payment decrease of $310,444 (0.001%) for all payers and $199,238 (0.001%) for Medicare. For all other pressure ulcers, the Hospital-Acquired Conditions Initiative reduced hospital payment in 20,246 (0.81%) cases (including 18,953 cases with present-on-admission ulcers), reducing statewide payment by $62,538,586 (0.21%) for all payers and $47,237,984 (0.32%) for Medicare.
CONCLUSION: The total financial effect of the 2008 payment changes for pressure ulcers was negligible. Most payment decreases occurred by removal of comorbidity payments for present-on-admission pressure ulcers other than Stages III and IV. The removal of payment for hospital-acquired Stage III and IV ulcers by implementation of the HACI policy was 1/200th that of the removal of payment for other types of pressure ulcers that occurred in implementation of the Hospital-Acquired Conditions Initiative.
© 2015, Copyright the Authors Journal compilation © 2015, The American Geriatrics Society.

Entities:  

Keywords:  Medicare; hospital-acquired conditions; payment; pressure ulcer

Mesh:

Year:  2015        PMID: 26140454      PMCID: PMC5278926          DOI: 10.1111/jgs.13475

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  8 in total

1.  Hospital-acquired pressure ulcers: a comparison of costs in medical vs. surgical patients.

Authors:  K Beckrich; S A Aronovitch
Journal:  Nurs Econ       Date:  1999 Sep-Oct       Impact factor: 1.085

2.  Hospital report cards for hospital-acquired pressure ulcers: how good are the grades?

Authors:  Jennifer A Meddings; Heidi Reichert; Tim Hofer; Laurence F McMahon
Journal:  Ann Intern Med       Date:  2013-10-15       Impact factor: 25.391

3.  Medicaid program; payment adjustment for provider-preventable conditions including health care-acquired conditions. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2011-06-06

4.  Pressure ulcers: avoidable or unavoidable? Results of the National Pressure Ulcer Advisory Panel Consensus Conference.

Authors:  Joyce M Black; Laura E Edsberg; Mona M Baharestani; Diane Langemo; Margaret Goldberg; Laurie McNichol; Janet Cuddigan
Journal:  Ostomy Wound Manage       Date:  2011-02       Impact factor: 2.629

5.  High cost of stage IV pressure ulcers.

Authors:  Harold Brem; Jason Maggi; David Nierman; Linda Rolnitzky; David Bell; Robert Rennert; Michael Golinko; Alan Yan; Courtney Lyder; Bruce Vladeck
Journal:  Am J Surg       Date:  2010-10       Impact factor: 2.565

6.  Quality of care for hospitalized medicare patients at risk for pressure ulcers.

Authors:  C H Lyder; J Preston; J N Grady; J Scinto; R Allman; N Bergstrom; G Rodeheaver
Journal:  Arch Intern Med       Date:  2001-06-25

7.  Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates; payments for graduate medical education in certain emergency situations; changes to disclosure of physician ownership in hospitals and physician self-referral rules; updates to the long-term care prospective payment system; updates to certain IPPS-excluded hospitals; and collection of information regarding financial relationships between hospitals. Final rules.

Authors: 
Journal:  Fed Regist       Date:  2008-08-19

Review 8.  Pressure ulcer pain: a systematic literature review and national pressure ulcer advisory panel white paper.

Authors:  Barbara Pieper; Diane Langemo; Janet Cuddigan
Journal:  Ostomy Wound Manage       Date:  2009-02       Impact factor: 2.629

  8 in total
  4 in total

1.  Consistency of pressure injury documentation across interfacility transfers.

Authors:  Lee Squitieri; David A Ganz; Carol M Mangione; Jack Needleman; Patrick S Romano; Debra Saliba; Clifford Y Ko; Daniel A Waxman
Journal:  BMJ Qual Saf       Date:  2017-07-28       Impact factor: 7.035

2.  Performance Assessment of a Humidity Measurement System and Its Use to Evaluate Moisture Characteristics of Wheelchair Cushions at the User-Seat Interface.

Authors:  Zhuofu Liu; Haifeng Cheng; Zhongming Luo; Vincenzo Cascioli; Andrew I Heusch; Nadia R Nair; Peter W McCarthy
Journal:  Sensors (Basel)       Date:  2017-04-05       Impact factor: 3.576

3.  Incidence of hospital-acquired pressure ulcers in patients with "minimal risk" according to the "Norton-MI" scale.

Authors:  Isabel Díaz-Caro; Soledad García Gómez-Heras
Journal:  PLoS One       Date:  2020-01-08       Impact factor: 3.240

4.  Grade IV Sacral Sore Treated with an Ointment Rich in PUFAs, Ceramides, and Antimicrobial Peptides.

Authors:  Marta Cassini; Irina Saretzky
Journal:  Case Rep Dermatol Med       Date:  2022-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.